Search results
Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug By Investing.com
Investing.com· 2 days agoFulcrum Therapeutics (ticker: NASDAQ:FULC) has entered into a significant collaboration with Sanofi...
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 days agoWe can compare a company's cash burn to its market capitalisation to get a sense for how many new...
Fulcrum Therapeutics stock target lifted, maintains buy on Sanofi deal By Investing.com
Investing.com· 3 days agoOn Monday, Stifel, a financial services firm, raised its price target on shares of Fulcrum...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the...
Morningstar· 3 days agoFulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives ...
FULC’s latest rating updates from top analysts. – Knox Daily
Knox Daily· 2 days agoFulcrum Therapeutics Inc’s filing revealed that its Principal Accounting Officer Tourangeau Greg unloaded Company’s shares for reported ...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 3 days agoConversely, general and administrative expenses decreased from $11.5 million to $10.1 million,...
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
BioPharma Dive via Yahoo Finance· 3 days agoThe deal gives the pharma partial rights to a medicine GSK once developed for heart disease but...
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move...
Zacks via Yahoo Finance· 18 hours agoThe consensus price target hints at a 69.2% upside potential forFulcrum Therapeutics (FULC). While...
Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod
RTT News· 3 days agoUnder the deal, Fulcrum retains full U.S. commercialization rights, while Sanofi obtains exclusive commercialization rights for losmapimod outside of the ...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter...
Morningstar· 3 days ago― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase ...